A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
Phase of Trial: Phase IV
Latest Information Update: 14 Jun 2018
At a glance
- Drugs Rasagiline (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms MODERATO
- Sponsors Teva Branded Pharmaceutical Products R&D
- 25 Apr 2015 Baseline data presented at the 67th Annual Meeting of the American Academy of Neurology.
- 26 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 29 Oct 2014 Planned End Date changed from 1 Oct 2014 to 1 Feb 2015 as reported byClinicalTrials.gov record.